

Curriculum Vitae

Personal Data

Title	Prof. Dr. med.
First name	Wolfram
Name	Klapper
Current position	Full Professor for Hematopathology
Current institution(s)/site(s), country	Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein Campus Kiel, Institute/ Department of Pathology, Hematopathology Section/Lymph Node Registry Address: Arnold-Heller-Str. 3, Bldg 14, 24105 Kiel Phone +49-431-500-15716 Fax +49-431-500-15714 E-mail wklapper@uni-kiel.de
Identifiers/ORCID	0000-0001-7208-4117

Qualifications and Career

Stages	Periods and Details
Degree programme	1992-1999 University of Kiel (Germany) / Medical School
Doctorate	
Stages of academic/professional career	<ul style="list-style-type: none"> • Since 2008 Head of the Hematopathology Section in the Department of Pathology, Christian-Albrechts-University Kiel & University Hospital Schleswig Holstein, Campus Kiel • 2007 Habilitation Board Certification (Pathology) • 2002-2008 Department of Pathology, University Hospital Kiel, Germany • 2000-2002 Residency (2nd Dept. Int. Med. Kiel and Pathology Kiel) • 2000 Visiting fellow Laboratory of Neuroscience, National Institute on Ageing, Baltimore, USA

Supplementary Career Information

None

Activities in the Research System Reference Pathologist for all German Lymphoma Study Groups in the Network of Competence Malignant Lymphomas (KML e. V.)

- Coordinating reference pathologists NHL-BFM pediatric lymphoma study group
- Coordinating reference pathologists GHSG Hodgkin lymphoma study group
- Coordinating reference pathologists European Mantle Cell Lymphoma Network
- Steering committee German Lymphoma Alliance and NHL-BFM

Supervision of Researchers in Early Career Phases

- PhD Students: Ulrike Paul (see Paul et al. *Leuk Lymphoma*. 2018 May;59(5):1213-1221)
Nicole Seifert (see Müller-Meinhardt, Seifert et al. *Hemasphere*. 2024 Jun 3;8(6):e84.
- In addition multiple medical students for their thesis.
- Currently ongoing: Clinician Scientists in CATCH ALL (Yalcin, Huber)

Scientific Results

Category A

1. Sureda-Gómez M, Iaccarino I, De Bolòs A, Meyer M, Balsas P, Richter J, Rodríguez ML, López C, Carreras-Caballé M, Glaser S, Nadeu F, Jares P, Clot G, Siciliano MC, Bellan C, Tornambè S, Boccacci R, Leoncini L, Campo E, Siebert R, Amador V, Klapper W. SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features. *Blood*. 2024 Jul 11;144(2):187-200. doi: 10.1182/blood.2023023242. PMID: 38620074.
2. Kroeze E, Iaccarino I, Kleisman MM, Mondal M, Beder T, Khouja M, Höppner MP, Scheijde-Vermeulen MA, Kester LA, Brüggemann M, Baldus CD, Cario G, Bladergroen RS, Garnier N, Attarbaschi A, Verdu-Amorós J, Sutton R, Macintyre E, Scholten K, Arias Padilla L, Burkhardt B, Beishuizen A, den Boer ML, Kuiper RP, Loeffen JLC, Boer JM, Klapper W. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma. *Blood*. 2024 Jul 4;144(1):74-83. doi: 10.1182/blood.2024023938. PMID: 38588489.
3. Reinke S, Bröckelmann PJ, Iaccarino I, Garcia-Marquez M, Borchmann S, Jochims F, Kotrova M, Pal K, Brüggemann M, Hartmann E, Sasse S, Kobe C, Mathas S, Soekler M, Keller U, Bormann M, Zimmermann A, Richter J, Fuchs M, von Tresckow B, Borchmann P, Schlößer H, von Bergwelt-Baildon M, Rosenwald A, Engert A, Klapper W. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. *Blood*. 2020 Dec 17;136(25):2851-2863. doi: 10.1182/blood.2020008553. PMID: 33113552.
4. Müller-Meinhard B, Seifert N, Grund J, Reinke S, Yalcin F, Kaul H, Borchmann S, von Tresckow B, Borchmann P, Plütschow A, Richter J, Engert A, Altenbuchinger M, Bröckelmann PJ, Klapper W. Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma. *Hemasphere*. 2024 Jun 3;8(6):e84. doi: 10.1002/hem3.84. PMID: 38836098; PMCID: PMC11145947.
5. Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluijn-Nelemans JC, Hermine O, Dreyling MH, Klapper W. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma

- Network. *J Clin Oncol*. 2016 Apr 20;34(12):1386-94. doi: 10.1200/JCO.2015.63.8387. Epub 2016 Feb 29. PMID: 26926679.
6. Heger JM, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmüller J, Kirst E, Reinke S, Klapper W, Bröckelmann PJ, Ferdinandus J, Kaul H, Schneider G, Schneider J, Schleifenbaum JK, Ullrich RT, Freihammer M, Awerkiew S, Lohmann M, Klein F, Nürnberg P, Hallek M, Rossi D, Mauz-Körholz C, Gattenlöhner S, Bräuninger A, Borchmann P, von Tresckow B, Borchmann S. Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma. *J Clin Oncol*. 2024 Sep 30;JCO2301867. doi: 10.1200/JCO.23.01867. Epub ahead of print. PMID: 39348625.
 7. Croci GA, Au-Yeung RKH, Reinke S, Staiger AM, Koch K, Oshlies I, Richter J, Poeschel V, Held G, Loeffler M, Trümper L, Rosenwald A, Ott G, Spang R, Altmann B, Ziepert M, Klapper W. SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status. *Ann Oncol*. 2021 Nov;32(11):1400-1409. doi: 10.1016/j.annonc.2021.08.1991. Epub 2021 Aug 24. PMID: 34438040.
 8. Koch K, Richter J, Hanel C, Huttmann A, Duhrsen U, Klapper W. Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation. *Haematologica*. 2022 Sep 1;107(9):2144-2153. doi: 10.3324/haematol.2021.279351. PMID: 35021600; PMCID: PMC9425313.
 9. Au-Yeung RKH, Padilla LA, Zimmermann M, Reinke S, Oshlies I, Escherich G, Woessmann W, Burkhardt B, Klapper W. Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma. *Leukemia*. 2023 Feb;37(2):488-491. doi: 10.1038/s41375-022-01757-0. Epub 2022 Nov 9. PMID: 36352192; PMCID: PMC9898023.
 10. Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, Thorns C, Hartmann S, Kluijn-Nelemans H, Hermine O, Dreyling M, Klapper W. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. *Blood*. 2018 Jan 25;131(4):417-420. doi: 10.1182/blood-2017-07-797019. Epub 2017 Dec 1. PMID: 29196411.

Category B

Academic Distinctions

2015 Plenary Session in Memory of Warren Sanger, Pediatric Cancer research Foundation, October 23, 2015 Varese, Italy

Other Information

Data protection and consent to the processing of optional data

If you provide voluntary information (marked as optional) in this CV, your consent is required. Please confirm your consent by checking the box below.

I expressly consent to the processing of the voluntary (optional) information, including “special categories of personal data”¹ in connection with the DFG’s review and decision-making process regarding my proposal. This also includes forwarding my data to the external reviewers, committee members and, where applicable, foreign partner organisations who are involved in the decision-making process. To the extent that these recipients are located in a third country (outside the European Economic Area), I additionally consent to them being granted access to my data for the above-mentioned purposes, even though a level of data protection comparable to EU law may not be guaranteed. For this reason, compliance with the data protection principles of EU law is not guaranteed in such cases. In this respect, there may be a violation of my fundamental rights and freedoms and resulting damages. This may make it more difficult for me to assert my rights under the General Data Protection Regulation (e.g. information, rectification, erasure, compensation) and, if necessary, to enforce these rights with the help of authorities or in court.

I may **revoke** my consent in whole or in part at any time – with effect for the future, freely and without giving reasons – vis-à-vis the DFG (postmaster@dfg.de). The lawfulness of the processing carried out up to that point remains unaffected. Insofar as I transmit “special categories of personal data” relating to third parties, I confirm that the necessary legitimation under data protection law exists (e.g. based on consent).

I have taken note of the DFG’s Data Protection Notice relating to research funding, which I can access at www.dfg.de/privacy_policy and I will forward it to such persons whose data the DFG processes as a result of being mentioned in this CV.

¹ Special categories of personal data are those “revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and (...) genetic data, biometric data for the purpose of uniquely identifying a natural person, data concerning health or data concerning a natural person’s sex life or sexual orientation” (Article 9(1) GDPR).